FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Food Ingredients News

Childhood Obesity Plan Needs Equal Participation From Food Companies

30 Sep 2016 --- The Government's Childhood Obesity Plan will only have the desired impact if it ensures the full and equal participation of all companies across every part of the food industry, the British Food Corporation (BRC) has said. 

Health & Nutrition News

Health Organization Grades America on Its Poor Diet

30 Sep 2016 --- Americans are eating too much of everything, according to a report card on the changing American diet published in Nutrition Action Healthletter. The ‘report card’ from The Center For Science in the Public Interest (CSPI), also states that it’s not just how much Americans are eating, but also what they eat, that needs work.

Health & Nutrition News

"It’s OK to Eat Sliced Bread", Says New Study

30 Sep 2016 --- A new study has revealed that eating bread can form part of a healthy diet. The research commissioned by the Irish Bread Bakers Association (IBBA) and carried out by the Irish Universities Nutrition Alliance (IUNA) suggests that bread contributes 20% to our fiber intake, 9% to our protein intake, while white bread only contributes 1% to our daily fat and sugar intake.

Health & Nutrition News

EU Novel Foods Approval for Heart Health Antioxidant

29 Sep 2016 --- DSM Nutritional Products has received European Union (EU) Novel Foods approval for resVida, a high purity trans-resveratrol. The ruling means resVida can be placed on the EU market as a novel food ingredient to be used in food supplements in capsule or tablet form, at doses of up to 150 mg per day.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html